Mcdaniel Terry & Co. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Mcdaniel Terry & Co. cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 192,473 shares of the company's stock after selling 2,310 shares during the period. Johnson & Johnson comprises approximately 2.8% of Mcdaniel Terry & Co.'s portfolio, making the stock its 15th largest position. Mcdaniel Terry & Co.'s holdings in Johnson & Johnson were worth $31,920,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of JNJ. Tallon Kerry Patrick acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $290,000. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Allegiance Financial Group Advisory Services LLC lifted its position in Johnson & Johnson by 8.4% in the fourth quarter. Allegiance Financial Group Advisory Services LLC now owns 3,329 shares of the company's stock valued at $481,000 after purchasing an additional 258 shares during the period. Finally, Schnieders Capital Management LLC boosted its holdings in Johnson & Johnson by 4.6% in the 4th quarter. Schnieders Capital Management LLC now owns 70,725 shares of the company's stock valued at $10,228,000 after purchasing an additional 3,120 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Bank of America lowered their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Price Performance

JNJ stock opened at $152.44 on Monday. The stock has a market capitalization of $366.78 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock's fifty day simple moving average is $153.75 and its 200-day simple moving average is $153.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.